1 / 9

Ps oriasis/Psoriatic A rthritis I mmunopathologic M echanisms (PsAIM)

Ps oriasis/Psoriatic A rthritis I mmunopathologic M echanisms (PsAIM). Centers Representitives Specialty UCSD A. Kavanaugh Rheum D.Boyle Rheum Gent D. Baeten Rheum Amsterdam P.P. Tak Rheum J.D. Bos/M.A de Rie Derm Leuven K.de Vlam Rheum

percy
Download Presentation

Ps oriasis/Psoriatic A rthritis I mmunopathologic M echanisms (PsAIM)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Psoriasis/Psoriatic Arthritis Immunopathologic Mechanisms (PsAIM) • CentersRepresentitivesSpecialty UCSD A. Kavanaugh Rheum D.Boyle Rheum Gent D. Baeten Rheum Amsterdam P.P. Tak Rheum J.D. Bos/M.A de Rie Derm Leuven K.de Vlam Rheum R. Lories Rheum Seattle (P.Mease) Rheum Glasgow I. McInnes Rheum Dublin D. Veale Rheum O.FitzGerald Rheum (B.Bresnihan) Rheum Newcastle D. Kane Rheum Rochester C. Ritchlin Rheum

  2. Psoriasis/Psoriatic Arthritis Immunopathologic Mechanisms (PsAIM) Aims • Ps/PsA sample collections.-Inventory of what is available for study. • Primary study-To assess/validate immunohistologic change in skin and synovial tissue as a surrogate marker in PsA.-Need to agree how we go about this. Have we enough samples?-Can we use tissues stained in different centres or should they all be done in one centre? -What markers should we look at first?

  3. Psoriasis/Psoriatic Arthritis Immunopathologic Mechanisms (PsAIM) (3) Is there an opportunity here to ask some additional questions? e.g. -As PsA is a more asymmetric disease, is the synovial involvement less uniform? -Are clinically uninvolved joints in PsA immunohistologically abnormal as in RA?  -Is there an opportunity here to ask some additional questions? -Are there SM changes that are specific to PsA? Doug Veale has suggested that the vascularity is distinct at macroscopic level, are there distinct vascular markers at cellular level? 

  4. Psoriasis/Psoriatic Arthritis Immunopathologic Mechanisms (PsAIM) -Are there parallels between skin and SM in response to treatment at immunohistologic level? -Do different subsets of PsA have different immunohistologic features? -Can we study mechanisms driving new bone formation using immmunohistology? -Can we gain a better understanding of the importance of adaptive vs innate immune responses in PsA joints and skin? -Study the joints and skin of Ps patients without MSK symptoms to gain insight into the early events in PsA.

  5. Inventory: Dublin

  6. Inventory: Gent

  7. Inventory: Amsterdam

  8. Inventory: Glasgow

  9. Inventory: Rochester

More Related